Clinical Therapeutics

Editorial comment
pp. 1321-1322(2)
Author: Walson P.D.

Rofecoxib: clinical pharmacology and clinical experience
pp. 1323-1338(16)
Author: Weaver A.L.

A review of the pharmacology and pharmacokinetics of inhaled fluticasone propionate and mometasone furoate
pp. 1339-1354(16)
Authors: Crim C.; Pierre L.N.; Daley-Yates P.T.

A review of the chemistry, biological action, and clinical applications of anabolic-androgenic steroids
pp. 1355-1390(36)
Author: Shahidi N.T.

Analysis of trials evaluating combinations of acetylsalicylic acid and dipyridamole in the secondary prevention of stroke
pp. 1391-1408(18)
Authors: Redman A.R.; Ryan G.J.

Risedronate: a new oral bisphosphonate
pp. 1409-1421(13)
Authors: Umland E.M.; Boyce E.G.

Upper gastrointestinal safety evaluation of parecoxib sodium, a new parenteral cyclooxygenase-2-specific inhibitor, compared with ketorolac, naproxen, and placebo
pp. 1422-1428(7)
Authors: Harris S.I.; Kuss M.; Hubbard R.C.; Goldstein J.L.

Tramadol/acetaminophen combination tablets and codeine/acetaminophen combination capsules for the management of chronic pain: a comparative trial
pp. 1429-1445(17)
Authors: Mullican W.S.; Lacy J.R.; TRAMAP-ANAG-006 Study Group

Rofecoxib versus codeine/acetaminophen in postoperative dental pain: a double-blind, randomized, placebo- and active comparator-controlled clinical trial
pp. 1446-1455(10)
Authors: Chang D.J.; Fricke J.R.; Bird S.R.; Bohidar N.R.; Dobbins T.W.; Geba G.P.

The role of losartan in the management of patients with heart failure
pp. 1456-1477(22)
Author: Dickstein K.

A comparison of renal-related adverse drug reactions between rofecoxib and celecoxib, based on the World Health Organization/Uppsala Monitoring Centre safety database
pp. 1478-1491(14)
Authors: Zhao S.Z.; Reynolds M.W.; Lefkowith J.; Whelton A.; Arellano F.M.

Cerivastatin versus branded pravastatin in the treatment of primary hypercholesterolemia in primary care practice in Canada: A one-year, open-label, randomized, comparative study of efficacy, safety, and cost-effectiveness
pp. 1492-1507(16)
Authors: McPherson R.; Hanna K.; Agro A.; Braeken A.; Canadian Cerivastatin Study Group

Efficacy and safety of ketoprofen lysine salt mouthwash versus benzydamine hydrochloride mouthwash in acute pharyngeal inflammation: a randomized, single-blind study
pp. 1508-1518(11)
Authors: Passali D.; Volonte M.; Passali G.C.; Damiani V.; Bellussi L.; MISTRAL Italian Study Group

Acute and chronic effects of brimonidine 0.2% on intraocular pressure and pulsatile ocular blood flow in patients with primary open-angle glaucoma: an open-label, uncontrolled, prospective study
pp. 1519-1528(10)
Authors: Vetrugno M.; Maino A.; Cantatore F.; Ruggeri G.; Cardia L.

Comparison of the efficacy of formoterol and salmeterol in patients with reversible obstructive airway disease: a multicenter, randomized, open-label trial
pp. 1529-1541(13)
Author: Condemi J.J.

Factors associated with clinical assessment of overactive bladder and selection of treatment
pp. 1542-1551(10)
Authors: Diokno A.; Lee P.; Zorn B.H.; Lenderking W.R.; Grossman M.A.; Bull S.A.; Albrecht D.

Effect of raloxifene on serum triglycerides in postmenopausal women: influence of predisposing factors for hypertriglyceridemia
pp. 1552-1565(14)
Authors: Mosca L.; Harper K.; Sarkar S.; O'Gorman J.; Anderson P.W.; Cox D.A.; Barrett-Connor E.

Pharmacoeconomics under defined contributions and tiered formularies
pp. 1568-1569(2)
Author: Lyles A.

Methodology for identifying patients at high risk for osteoporotic fracture
pp. 1570-1588(19)
Authors: Westfall G.; Littlefield R.; Heaton A.; Martin S.

A comparison of asthma-related expenditures for patients started on montelukast versus fluticasone propionate as monotherapy
pp. 1589-1600(12)
Authors: Bukstein D.A.; Henk H.J.; Luskin A.T.

Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two phase II studies
pp. 1601-1601(1)
Author: Bays H.E.